'Dark-horse' molecule is a potential new anti-cancer target

15-Aug-2013 - Australian researchers have identified a molecule called interleukin-11 as a potential new target for anti-cancer therapies. Until now, the importance of interleukin-11 in cancer development has been underestimated, but researchers have recently identified this molecule as a 'dark horse' for the ...

Pathway controlling cell growth revealed

19-Feb-2013 - A Melbourne-based research team has discovered a genetic defect that can halt cell growth and force cells into a death-evading survival state. The finding has revealed an important mechanism controlling the growth of rapidly-dividing cells that may ultimately lead to the development of new ...

Nanosensors support skin cancer therapy

15-Feb-2013 - Malignant melanoma is the most aggressive type of skin cancer. In more than 50 percent of affected patients a particular mutation plays an important role. As the life span of the patients carrying the mutation can be significantly extended by novel drugs, it is very important to identify those ...

iTeos Therapeutics launched to develop immunomodulators

New Company to Focus on Developing Novel Immunotherapy Compounds for Cancer Treatment

07-May-2012 - The Ludwig Institute for Cancer Research (LICR) announced the launch of a private biotechnology enterprise, iTeos Therapeutics SA, to develop a pre-clinical pipeline of immunomodulators to stimulate the immune system’s ability to attack cancer. Founded by LICR with the de Duve Institute at the ...

4-Antibody AG Forms Multi-target Oncology Research and Development Alliance with the Ludwig Institute

26-May-2011 - 4-Antibody AG announced the signing of a multi-target research alliance with the Ludwig Institute for Cancer Research (LICR). Under the terms of the deal, the focus of the research and clinical development alliance will be on a series of molecular targets which are important in the suppression of ...

Kyowa Hakko Kogyo Co., Ltd. licenses its in-house developed antibody KW-2871 targeting malignant melanoma to Life Science Pharma

07-Mar-2007 - Kyowa Hakko Kogyo Co., Ltd. (KHK) agreed to license its in-house developed antibody KW-2871 to US pharmaceutical development company Life Science Pharmaceuticals (LSP). KHK grants to LSP an exclusive world-wide license to develop and market the compound. KW-2871 will be continued to be developed ...

Avidex establishes research collaboration with Ludwig Institue for Cancer Research

15-Mar-2005 - Avidex announced that it has established a research collaboration with the Ludwig Institute for Cancer Research (LICR). The collaboration is based on one of Avidex's soluble monoclonal T cell receptors (mTCRs) which targets the tumour associated antigen NY-ESO-1. NY-ESO-1 was discovered by ...